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Abstract Mast cells play important roles in host defence
against pathogens, as well as being a key effector cell in dis-
eases with an allergic basis such as asthma and an increasing
list of other chronic inflammatory conditions. Mast cells ini-
tiate immune responses through the release of newly synthe-
sised eicosanoids and the secretion of pre-formed mediators
such as histamine which they store in specialised granules.
Calcium plays a key role in regulating both the synthesis
and secretion of mast-cell-derived mediators, with influx
across the membrane, in particular, being necessary for de-
granulation. This raises the possibility that calcium influx
through P2X receptors may lead to antigen-independent se-
cretion of histamine and other granule-derived mediators from
human mast cells. Here we show that activation of P2X7
receptors with both ATP and BzATP induces robust calcium
rises in humanmast cells and triggers their degranulation; both
effects are blocked by the P2X7 antagonist AZ11645373, or
the removal of calcium from the extracellular medium.
Activation of P2X1 receptors with αβmeATP also induces
calcium influx in human mast cells, which is significantly
reduced by both PPADS and NF 449. P2X1 receptor activa-
tion, however, does not trigger degranulation. The results in-
dicate that P2X7 receptors may play a significant role in con-
tributing to the unwanted activation of mast cells in chronic
inflammatory conditions where extracellular ATP levels are
elevated.
Keywords P2X .Mast cells . ATP . Degranulation
Abbreviations
ATP Adenosine 5′-triphosphate
αβmeATP Alpha beta methyl ATP
BzATP 2′(3′)-O-(4-Benzoylbenzoyl)-ATP
NF 449 4,4′,4″,4″′-[Carbonylbis(imino-5,1,3-
benzenetriyl-bis(carbonylimino))]tetrakis-1,3-
benzenedisulfonic acid, octasodium salt
PPADS Pyridoxal-5-phosphate-6-azophenyl-2′,4′-
disulphonic acid
Introduction
Mast cells have long been recognised as key cells involved in
immune surveillance. As tissue resident cells, they represent a
first line of defence to infection and participate in host protec-
tion. In health, the rapid secretion of inflammatory mediators,
most notably histamine and proteases, empowers the cells to
respond immediately to tissue injury and aid in detoxification,
wound healing and tissue remodelling [1]. Consistent with
these functions, mast cells are found in tissues which interface
the external environment such as skin, airways and gut and are
closely associated with blood vessels and sensory nerves.
Receptors expressed on their surface enable them to sense
the surrounding environment and respond appropriately
through the secretion of a wide variety of mediators [2].
However, it has also long been recognised that the inappropri-
ate and/or chronic activation of mast cells is associated with
the pathology and symptoms of a wide range of diseases; as
the effectors of IgE-mediated type 1 hypersensitivity reac-
tions, mast cells have a well-recognised role in allergic disor-
ders including food allergies, atopic dermatitis, anaphylaxis,
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rhinitis and asthma. A role for mast cells in other chronic and
painful inflammatory conditions including irritable bowel
syndrome, progressive kidney disease and migraine is also
implicated, although in these cases the triggers involved in
mast cell activation are less clear [1, 3–5].
Extracellular ATP is a well-known danger signal associated
with inflammatory conditions and has therefore been
highlighted as a potential activator of mast cells [6, 7]. In
rodent mast cells, ATP, independently of IgE-mediated signal-
ling, acts on P2 purinoceptors [8, 9] of which there are two
major groups—the ionotropic P2X receptors and the metabo-
tropic P2Y receptors [10]. P2X receptors are non-selective
cation channels which are known to conduct large fractional
calcium currents [11] mediating diverse downstream process-
es such as exocytosis, cytokine release and smooth muscle
contraction in a variety of cells [12–14]. It has been shown
many times that ATP can induce calcium fluxes in various
types of rodent mast cell [15–17], linked to downstream ef-
fects such as degranulation [9, 18] and chemotaxis [19]. There
are reports that ATP can exert effects on secretion in human
mast cells [20, 21], but there are very few specific studies
identifying the receptor subtypes involved. The importance
of gaining further knowledge with regards the functional role
of P2X receptors in human mast cells has recently come to the
fore following the discovery that loss-of-function mutations in
the P2X7R reduces asthma risk and severity in children [22];
P2X7R on mast cells have also been identified as important
contributors to intestinal inflammation in mice and observed
to be increased in humans with Crohn’s disease [23]. The
potential functional roles of P2X receptors in human mast
cells are as yet undetermined, and the involvement of P2X
receptors in the ATP-mediated effects on secretion in human
mast cells has not been fully explored [7, 24].
We have previously demonstrated the presence of function-
al P2X1, P2X4 and P2X7 receptors in the LAD 2 human mast
cell line and primary human lung mast cells (HLMCs) [25].
The purpose of this study was firstly to determine whether
P2X1 and 7 purinoceptors conduct significant calcium in-
fluxes in the LAD 2 human mast cell line, and second, to
investigate if any calcium fluxes induced via P2X1 and 7
receptor activation can induce human mast cell degranulation.
Materials and methods
Human mast cells
LAD 2 mast cells, derived from a patient with mast cell leu-
kaemia, were a gift from Dr. D. Metcalfe (National Institute of
Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD) and cultured in StemPro-34 SFM serum-free
complete medium (Invitrogen Life Technologies), with
100 ng/ml SCF as previously described [26]. Half the medium
was replaced every 7 days. Cells were maintained at 37 °C in a
humidified atmosphere of 5 % CO2 incubator.
Calcium imaging
LAD 2 cells were plated on poly-L-lysine (0.1 %)-coated cov-
erslips, loaded with 1 μMFura 2-AM and visualised on a Zeiss
Axiovert microscope. Cells were perfused with imaging exter-
nal solution containing (in mM) 142 NaCl, 5 NaHCO3, 10
HEPES, 16 glucose, 2 KCl, 2 CaCl2, 1 MgCl2 and 0.1 % bo-
vine serum albumin (BSA; pH 7.3, NaOH). Images were taken
at 1-s intervals at 340 and 380 nm of light (15-ms exposure).
The emitted light was passed through a 510–540-nm band pass
filter before detection using a cascade 512B CCD camera
(Roper Scientific, Photometrics UK). Data was collected and
analysed usingMetamorph® software (Meta Imaging), and fur-
ther analysis and graphing were performed using Origin
graphing software (OriginPro7.5, Origin corporation, USA).
All fluorescence values are background subtracted and
displayed as ratio changes. Data represents the mean±standard
error of mean (SEM) unless otherwise stated. Significance was
assessed using a Student’s t test unless otherwise stated. In all
figures, * = p < 0.05, ** = p < 0.01. Responding cells were
counted as those where calcium levels in response to drug rose
by more than 5 standard deviations over the baseline in a spec-
ified period of time. All concentrations of agonists used were
based on previous experiments demonstrating the functional
presence of P2X receptors in human mast cells [25].
β-Hexosaminidase release assays
LAD 2 cells were plated in a 96-well V bottomed plate in
imaging buffer and incubated at 37 °C for 10 min.
Antagonists were then added as indicated and incubated with
the cells at 37 °C for 5–10 min before the addition of agonists.
Cells were then incubated at 37 °C for an additional 20 min
before being centrifuged (2500RPM, 10 min, 4 °C) and the
supernatants removed. Supernatants were incubated with sub-
strate (2 mM 4-nitrophenyl N-acetyl-β-D-glucosaminide di-
luted in 0.2M citrate buffer) for 2 h at 37 °C. The reaction was
stopped by the addition of Tris-HCl (1 M, pH 9.0) and absor-
bance at 405 nm measured (Expert Plus Microplate reader,
Biochrom Ltd). Spontaneous β-hexosaminidase release was
determined by the addition of imaging buffer only. Total β-
hexosaminidase content was determined by the addition of
Triton X-100 (0.06 %) to lyse the cells. Background readings
were determined for later subtraction from wells containing
only release buffer and substrate. All test conditions were
done in duplicate in a single experiment and each experiment
repeated a minimum of three times. Average background
values and average spontaneous β-hexosaminidase release
values were subtracted from the reading for each well.
Release was then expressed as a percentage of the average
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total β-hexosaminidase content determined from the Triton-
treated wells. Results are displayed as mean±SEM. For all
statistical data comparisons, percentage values were log10 con-
verted to transform the data before a one-wayANOVAwith post
hoc Tukey test was performed. In all figures, * = p < 0.05,
** = p < 0.01. The LDH cytotoxicity assays were conducted
using a kit (Roche) as per the manufacturer’s instructions.
Reagents
StemPro 34 SFMmedia and nutrient supplement were obtain-
ed from Invitrogen Life Technologies (Paisley, UK). Stem cell
factor was obtained from R&D systems (Abingdon, UK).
Nucleotides, apyrase, PPADS, poly-L-lysine, EGTA, D-
glutamic acid, 4-nitrophenyl N-acetyl-β-D-glucosaminide,
Trizma HCl, citric acid and HEPES were purchased from
Sigma-Aldrich (Poole, Dorset, UK). Physiological salts, sodi-
um hydroxide and glucose were purchased from BDH
anachem. Fura-2 AM was purchased from Calbiochem
(Merck Chemicals Ltd., Nottingham, UK) or Invitrogen Ltd.
(Paisley, UK). Cesium hydroxide was purchased from ICN
Biomedicals Inc. (USA). NF 449 was purchased from Tocris
Bioscience (Bristol, UK). AZ 11645373 was a generous gift
from AstraZeneca R&D (Charnwood, UK).
Results
P2X1 receptor activation induces calcium fluxes in resting
LAD 2 cells
To examine whether P2X1 receptors could induce calcium
influx in LAD 2 cells, the P2X1 agonist αβmeATP was used.
Applying αβmeATP (10 μM) to LAD 2 cells loaded with
Fura-2 AM induced a transient increase in intracellular calci-
um levels (Fig. 1a, b). When cells were pre-incubated with
Fig. 1 P2X1-mediated calcium
fluxes in LAD 2 cells. Example
traces (a, c, e), or average
responses from one experiment
(b, d, f) showing calcium fluxes
induced by 10 μM αβmeATP in
LAD 2 cells under differing
conditions. a, b following pre-
incubation with 4 U/ml apyrase,
recorded in the presence of 2 mM
calcium; c, d no pre-incubation
with apyrase, recorded in the
presence of 2 mM calcium; e, f
following pre-incubation with
4 U/ml apyrase, recorded in
calcium free external solution. g
Summary of the mean peak
change in fluorescence ratio
induced by 10 μM αβmeATP in
LAD 2 cells following pre-
incubation or no pre-incubation
with 4 U/ml apyrase (independent
t test, p< 0.01, n= 126 and n = 79
respectively). h Summary of the
mean peak change in fluorescence
ratio induced by 10 μM
αβmeATP in LAD 2 cells in the
presence or absence of
extracellular calcium
(independent t test, p < 0.01,
n= 126 and n= 136 respectively).
Data is mean ± SEM and is data
from one representative
experiment (b, d, f) or pooled data
from three separate experiments
(g, h). Drug application is
indicated by the bars above the
traces
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apyrase (4 U/ml, Grade VII) to avoid pre-existing
desensitisation of P2X1 receptors, 95 % of cells responded
to an initial application of αβmeATP (10 μM) with a mean
peak change in fluorescence of 0.087±0.003 a.u. (Fig. 1a, b).
This change in fluorescence declined rapidly in the presence
of agonist, and a second application failed to elicit a response,
consistent with the characteristic desensitisation properties of
P2X1 receptors [27, 28]. A significant decrease in the ampli-
tude of the calcium response was observed when cells were
not pre-incubated with apyrase (independent t test, p<0.01,
Fig. 1c, d, g) supporting the presence of pre-existing
desensitisation. In all further experiments where P2X1 recep-
tors were studied, cells were pre-incubated with apyrase (4 U/
ml, Grade VII, 1 h). When the same experiment was per-
formed in the absence of external calcium (0 mM calcium,
3 mM MgCl2, 3 mM EGTA), 59 % of cells responded to an
initial application of αβmeATP (10 μM) with a mean peak
change in fluorescence of 0.028 ± 0.002 a.u. (Fig. 1e, f).
Again, this was a significant reduction in the amplitude of
the response when compared to that obtained in the presence
of external calcium (independent t test, p<0.01, Fig. 1h). This
indicates that the predominant pathway for the rise in intracel-
lular calcium is from the external solution, not release from
intracellular stores, supporting the involvement of P2X
receptors.
The calcium influx induced by 10 μM αβmeATP was
significantly reduced (independent t test, p<0.01, n=59/75)
in the presence of the general P2X receptor antagonist PPADS
(mean peak ΔF340/380 under control conditions was 0.087
± 0.004 a.u. (n= 59 cells, three experiments); mean peak
ΔF340/380 in the presence of PPADS was 0.027±0.002 a.u.
(n=75 cells, three experiments) (data not shown)). The more
selective P2X1 antagonist NF 449 (1 μM) also significantly
inhibited the αβmeATP (10 μM)-induced calcium influx (in-
dependent t test, p<0.01), where the mean peak change in
fluorescence was reduced from 0.148±0.008 a.u. to 0.067
±0.007 a.u. (Fig. 2), supporting P2X1 receptor involvement.
In summary, a transient calcium rise was elicited in LAD 2
cells by the partially selective P2X1 agonist αβmeATP. This
rise was reduced in the absence of pre-incubation with apyrase
and in the absence of extracellular calcium indicating P2X1
receptor involvement. This calcium flux was sensitive to
blockade by both PPADS and NF 449, supporting P2X1 re-
ceptor involvement. Taken together, these data indicate that
P2X1 receptors stimulate calcium influx in LAD 2 cells under
physiological conditions.
P2X7 receptor activation induces calcium fluxes in resting
LAD 2 cells
Previous electrophysiological experiments we have reported
demonstrating the functional expression of P2X7 receptors in
human mast cells were conducted in low divalent external
solution to enhance the magnitude of the signals. Therefore,
we first successfully demonstrated the activation of P2X7 re-
ceptors under physiological conditions in LAD 2 cells in patch
clamp experiments (Supplementary Fig. S1) before measuring
calcium fluxes.
High concentrations of ATP (5mM) applied to LAD 2 cells
loaded with Fura-2 AM induced large calcium influxes
Fig. 2 NF 449 antagonism of P2X1-mediated calcium influx in LAD 2
cells. Example traces (a, c) and average responses from a single
experiment (b, d) showing calcium fluxes in response to 10 μM
αβmeATP in LAD 2 cells in the presence (b, d) or absence (a, c) of
1 μM NF 449. e Summary of the mean peak change in fluorescence in
response to 10 μM αβmeATP in LAD 2 cells in the presence, or absence
of 1 μM NF 449 (independent t test, p < 0.01, n= 90/82). Data is mean
± SEM and is data from one representative experiment (b, d) or pooled
data from three separate experiments (e). All cells were pre-incubated
with apyrase (4 U/ml, 1 h). NF 449 was superfused for 5 min prior to
agonist and antagonist application. Drug application is indicated by the
bars above the traces
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(Fig. 3). When stimulated in the presence of extracellular cal-
cium, 99% of cells responded to 5mMATP, with a mean peak
change in fluorescence of 0.379±0.011 a.u. The calcium rise
began relatively slowly, was non-desensitising and increased
during the time of agonist application, corresponding to the
characteristics of the current identified previously in patch
clamp experiments [25]. Sometimes, a smaller, rapid phase
of calcium entry preceded the main calcium rise (seen in
Fig. 3a); this was most likely due to the activation of other
P2X receptor subtypes (1 and possibly 4) and could also in-
clude P2Y-receptor-mediated calcium store release. When the
experiment was repeated in the absence of external calcium,
70 % of cells responded to 5 mM ATP with a mean peak
change in fluorescence of 0.038 ± 0.006 a.u. (Fig. 3c, d).
Under these conditions, the main calcium rise was abolished
(independent t test, p<0.01, Fig. 3g) with a smaller, rapidly
declining calcium signal corresponding to the activation of
other receptors as described above. When the cells were per-
fused with the selective P2X7 antagonist AZ 11645373
(1 μM, 2 min) prior to ATP application, 98 % of cells
responded with a mean peak change in fluorescence of
0.071±0.006 a.u. (Fig. 3e, f). Again, the main calcium rise
was abolished (independent t test, p<0.01, Fig. 3g) leaving a
similar small transient calcium signal, like that seen in calcium
free conditions. The kinetics of the response to 5 mM ATP,
along with the heavy dependence on external calcium levels,
indicates P2X7 receptor involvement. This is supported by
sensitivity to the selective P2X7 antagonist AZ 11645373.
Due to the non-selective actions of ATP, which also poten-
tially activates other P2X and P2Y receptor subtypes, these
experiments were repeated using the more selective agonist
BzATP. BzATP also activates P2X1 receptors; however, the
Fig. 3 P2X7-mediated calcium
fluxes in LAD 2 cells induced by
ATP. Example traces (a) and the
average response (b) from a
single experiment showing the
calcium rise induced by 5 mM
ATP in the presence of calcium in
LAD 2 cells. Example traces (c)
and average response (d) from a
single experiment showing the
calcium signal induced by 5 mM
ATP in the absence of
extracellular calcium in LAD 2
cells. Example traces (e) and
average response (f) from a single
experiment showing the calcium
signal induced by 5 mM ATP in
the presence of AZ 11645373 and
extracellular calcium in LAD 2
cells. g Summary of the mean
peak change in fluorescence
induced by 5 mM ATP in the
presence or absence of
extracellular calcium
(independent t test, p < 0.01,
n= 137/74) and in the presence of
AZ 11645373 (independent t test,
p< 0.01, n = 137/58). Data is
mean ± SEM and is data from one
representative experiment (b, d, f)
or pooled data from three to five
separate experiments (g). Drug
application is indicated by the
bars above the traces
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contribution of these receptors to any response seen is likely to
be small and transient, especially as cells were not pre-
incubated with apyrase for these experiments. BzATP
(300 μM) also elicited a calcium rise in LAD 2 cells (Fig. 4)
with similar kinetics to the ATP response, a slowly activating,
gradually increasing signal, representing facilitation of the
P2X7 receptor. In the presence of extracellular calcium,
98 % of cells responded to BzATP (300 μM) with a mean
peak change in fluorescence of 0.229±0.011 a.u. (Fig. 4a,
b). This was significantly reduced in the absence of external
calcium where 91 % of cells (Fig. 4c, d) responded with a
mean peak change in fluorescence of 0.043±0.004 a.u. (inde-
pendent t test, p<0.01, Fig. 4g). As with ATP, the large calci-
um signal seen in response to BzATP in the presence of cal-
cium was also abolished by the selective P2X7 antagonist AZ
11645373 (mean peak change in fluorescence following AZ
11645373 treatment of 0.074±0.005 a.u.; independent t test,
p<0.01, Fig. 4e, f, g), further supporting P2X7 receptor in-
volvement in this response.
When applying BzATP (300 μM) after a facilitating appli-
cation of ATP (5 mM), a second calcium rise with similar
kinetics was seen (Fig. 5a, b). The initial ATP application
would be expected to desensitise other P2X and P2Y receptors
before the application of BzATP, thereby further isolating the
P2X7-mediated calcium rise. When applied in the presence of
calcium, the mean peak change in fluorescence in response to
300 μM BzATP was 0.203±0.011 a.u. This response was
abolished in the absence of calcium (mean peak change
in fluorescence of −0.031 ± 0.002 a.u.; independent t
test, p< 0.01, Fig. 5c, d), and in the presence of AZ
11645373 (mean peak change in fluorescence of 0.055
± 0.015 a.u.; independent t test, p < 0.01, Fig. 5e, f),
further supporting evidence that the calcium rise was
mediated by P2X7 receptors.
Fig. 4 P2X7-mediated calcium
fluxes in LAD 2 cells induced by
BzATP. Example traces (a) and
average response (b) from a
single experiment showing the
calcium rise induced by 300 μM
BzATP in the presence of
extracellular calcium in LAD 2
cells. Example traces (c) and
average response (d) from a
single experiment showing the
calcium signal induced by
300 μM BzATP in the absence of
extracellular calcium in LAD 2
cells. Example traces (e) and
average response (f) from a single
experiment showing the calcium
signal induced by 300 μM
BzATP in the presence of AZ
11645373 and extracellular
calcium in LAD 2 cells. g
Summary of the mean peak
change in fluorescence induced
by 300 μM BzATP in the
presence or absence of
extracellular calcium
(independent t test, p < 0.01,
n= 137/74) and in the presence of
AZ 11645373 (independent t test,
p< 0.01, n = 137/58). Data is
mean ± SEM and is data from one
representative experiment (b, d, f)
or pooled data from three separate
experiments (g). Drug application
is indicated by the bars above the
traces
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The finding that high concentrations of both ATP and
BzATP bring about calcium rises in LAD 2 cells which are
dependent on extracellular calcium and are sensitive to the
P2X7 selective antagonist AZ 11645373 indicate that these
responses are mediated to a large extent by P2X7 receptors.
ATP-induced mediator release in LAD 2 cells
β-Hexosaminidase is a granule-associated mediator known to
be released by LAD 2 cells upon stimulation with antigen
[29]. To examine the potential role of P2X receptors in human
mast cell mediator release, a concentration response curve for
β-hexosaminidase release from LAD 2 cells in response to
ATP was constructed (Fig. 6). There was no detectable release
at low concentrations of ATP (1 and 10 μM), indicating a lack
of P2X1-mediated secretion. Raising the concentration to 100
and 300 μM caused very low levels of release (0.5±0.5 and
2.4±1.2 %, respectively). At high concentrations of ATP (1, 3
and 5 mM), β-hexosaminidase release was markedly in-
creased, appearing to plateau at 5 mM ATP with release of
63.9±5.7 %; this coincides with the concentrations of ATP
that would activate P2X7 receptors. The concentration re-
sponse mean data was fitted using the Hill equation, which
yielded an EC50 value of 0.84 mM ATP.
Due to the fact that prolonged exposure to ATP can lead to
apoptosis in P2X7-expressing cells [30, 31], it was important
Fig. 5 BzATP-mediated calcium
fluxes in LAD 2 cells following
ATP application. Example traces
(a) and average response (b) from
a single experiment showing the
calcium rise in response to 5 mM
ATP followed by 300 μMBzATP
in the presence of extracellular
calcium. Example traces (c) and
average response (d) from a
single experiment showing the
calcium rise in response to 5 mM
ATP followed by 300 μMBzATP
in the absence of extracellular
calcium. Example traces (e) and
average response (f) from a single
experiment showing the calcium
rise in response to 5 mM ATP
followed by 300 μM BzATP in
the presence of AZ 11645373. g
Summary of the mean peak
change in fluorescence induced
by 300 μMBzATP following a 5-
mM ATP application in the
presence or absence of
extracellular calcium
(independent t test, p < 0.01,
n= 137/78), or in the presence of
absence of AZ 11645373
(independent t test, p < 0.01,
n= 137/49). Data is mean ± SEM
and is data from one
representative experiment (b, d, f)
or pooled data from three separate
experiments (g). Drug application
indicated by the bars above the
traces
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to establish that the β-hexosaminidase in the supernatant at
high concentrations of ATPwas not due to cell lysis and death.
Cell counts and Trypan blue dye exclusion indicated that the
overall percentage of dead cells following a release assay was
similar when they were stimulated with either 1 μM (4.6%) or
5 mM (6.3 %) ATP (Table 1). This indicates that the β-
hexosaminidase in the supernatant was present due to receptor
stimulation and not non-specific cell death or apoptosis.
The protocol for these release assays involved incubating
the cells with agonist for 20min. Unlike imaging experiments,
where the solution bathing the cells was continually refreshed,
in this experiment the cells were in contact with the same
solution for the whole time period. This is important as mast
cells have been reported to express ectonucleotidases [32, 33]
which can degrade ATP to ADP, AMP and adenosine, all of
which could secondarily activate mast cells via receptors other
than P2X and ATP sensitive P2Y receptors. It is therefore
important to examine each of the receptor subtypes in isola-
tion with more stable and selective agonists.
Lack of P2X1-mediatedβ-hexosaminidase release in LAD
2 cells
To specifically address the role of P2X1 receptors in human
mast cell secretion, LAD 2 cells were stimulated with
αβmeATP (1, 10 and 30 μM) either with or without the an-
tagonist NF 449 (1 μM) following pre-incubation with apy-
rase (Grade VII, 4U/ml, 1 h). These compounds induced no
discernable pattern of stimulation or inhibition of release
(Fig. 7, one-way ANOVA, p>0.05).
P2X7-mediated β-hexosaminidase release in LAD 2 cells
When stimulated with the more selective agonist BzATP, a
dose-dependent release of β-hexosaminidase was again seen
with striking release at 300 μM BzATP (88.8 ± 12.5 %,
Fig. 8a). This release was completely abolished in the pres-
ence of AZ 11645373 (3.4±1.6 %, one-way ANOVA, post
hoc Tukey test, p<0.05). This further suggests the involve-
ment of P2X7 receptors in this mediator release. Again, cell
viability counts revealed a similar percentage of dead cells
following the release assay in wells stimulated with 1 μM
BzATP (4.5 %) and 300 μM BzATP (4.9 %; Table 1). LDH
measurements indicated a lack of significant cytotoxicity
(300 μM BzATP associated with 1.6 %±0.5 % cytotoxicity,
Fig. 8b), supporting the hypothesis that the β-hexosaminidase
was actively secreted following stimulation of P2X7 receptors
rather than leaking from dead and dying cells. A lack of ex-
ternal calcium also abolished release indicating a physiologi-
cal process (data not shown).
Discussion
This study aimed to determine whether P2X receptors could
induce calcium fluxes and degranulation in human mast cells.
Single-cell imaging experiments revealed that calcium flux
through P2X1 receptors is fast and transient, augmented by
pre-incubation with apyrase, desensitises upon repeated ago-
nist application and is antagonised by PPADS and NF 449.
The effects of apyrase on αβmeATP-induced calcium signals
are consistent with the view that P2X1 receptors may become
desensitised by the presence of ATP in the growth media, an
effect which may obscure the function of these receptors in
in vitro studies [34, 35]. P2X7-mediated calcium rises in hu-
man mast cells by contrast are sustained and facilitate over the
duration of agonist application and are antagonised by AZ
11645373. In the absence of extracellular calcium, a small
calcium signal could still be seen to both αβmeATP and
Fig. 6 β-Hexosaminidase release in response to ATP in LAD 2 cells.
Concentration response curve to ATP showingβ-hexosaminidase release.
Data fit with the Hill equation (y=Vmax*x
n / (Kn+ xn), using Origin v7.5
software. Fit shown in red, no weighting applied. EC50 value of mean
data = 0.84 mM ATP. Hill slope = 3.5. Data is mean ± SEM, n = 4
experiments performed in duplicate or triplicate
Table 1 Cell viability following P2X7 receptor activation in β-
hexosaminidase release assays
Experiment % cells dead following release assay
1 μM ATP 5 mM ATP 1 μM BzATP 300 μM BzATP
1 3.6 9.5 4.5 3.9
2 4.5 3.5 7.7 5.0
3 2.9 2.6 1.3 5.8
4 7.5 9.7
Average 4.6 6.3 4.5 4.9
Table shows the percentage of dead cells present following release assays;
cell viability was determined by Trypan blue dye exclusion (cells stained
with 0.05 % Trypan blue dye in PBS); n= 3/4 experiments
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ATP in LAD 2 cells, suggesting that purinergic receptors can
also induce store-dependent calcium signals in these cells.
Moreover, as a residual calcium signal could also be seen
following antagonism of the P2X responses, it is likely that
these signals arise from P2Y receptors, all of which are report-
ed to be expressed in LAD 2 cells [36]. It therefore seems
likely that in native systems, complex calcium signals incor-
porating influx through P2X1 receptors, together with store-
released calcium signalling arising from activation of phos-
pholipase C coupled P2Y receptors, are likely to be generated
in mast cells exposed to micromolar levels of ATP. On the
other hand, when ATP levels are increased to millimolar con-
centrations, for example in pathological conditions, signals
generated by P2X1 receptors, and possibly P2Y receptors,
are likely to be reduced as a result of desensitisation and
superceded by calcium influx through P2X7 receptors. The
differences in the amplitude and kinetics of the calcium sig-
nals generated by different levels of ATP, and P2X1 versus
P2X7 receptors, are likely to have a significant impact on the
downstream functions each regulates in human mast cells
[37].
Due to the importance of mediator release in mediating
mast cell function and pathology [2], and the prominent role
calcium signalling plays in regulating secretion [38], the
downstream consequences of P2X receptor activation on mast
cell degranulation were evaluated. The main components of
mast cell granules include proteases such as tryptase,
chymase, carboxypeptidase and histamine. The lysosomal en-
zyme, β-hexosaminidase, is also stored and released from
mast cell granules and is therefore frequently used as a way
to measure mast cell degranulation in vitro [39]. Here, we
show that under conditions in which P2X1 receptors support
Fig. 7 P2X1 receptor activation
and β-hexosaminidase release in
LAD 2 cells. a, b, c Examples of
individual β-hexosaminidase
release assays (average of
duplicate wells) in response to
αβmeATP (1, 10 or 30 μM) with
or without NF 449 (1 μM). d
Summary of mean β-
hexosaminidase release in
response to αβmeATP (1, 10 or
30 μM) with or without NF 449
(1 μM). Cells were pre-incubated
with apyrase (Grade VII, 4U/ml,
1 h). Data is mean ± SEM, n = 3
experiments performed in
duplicate. One-way ANOVA,
p> 0.05
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calcium influx across the plasma membrane, no β-
hexosaminidase is released. Notably, a previous study in
LAD 2 mast cells reported that activation of P2Y receptors
also does not induce degranulation [36], supporting the notion
that in vivo, mast cells do not degranulate in response to low
levels of ATP. In contrast, at high concentrations of ATP, and
in response to BzATP, signif icant release of β -
hexosaminidase was observed. Moreover, the release of β-
hexosaminidase following P2X7 activation was dependent
upon extracellular calcium, indicating it resulted from regulat-
ed exocytosis of β-hexosaminidase rather than leakage from
dead or dying cells. The lack of cytotoxicity to high concen-
trations of BzATP was confirmed with an LDH assay. The
sensitivity of this β-hexosaminidase release to the selective
P2X7 antagonist AZ 11645373 is supporting evidence that
the release can be attributed to P2X7 receptors.
The results from this and other studies add to the growing
list of receptors identified on mast cells able to induce IgE-
independent activation [2], and show that degranulation of
mast cells is not solely regulated by calcium influx through
Orai channels [37], but may also couple to P2X7 receptors.
Already, a host of studies have reported ATP-induced media-
tor release in rodent mast cells, ranging from calcium-
dependent histamine release, to an upregulation in transcrip-
tion and secretion of pro-inflammatory cytokines [7]. In hu-
man mast cells, most studies to date have demonstrated mod-
ification of IgE-stimulated mediator release but not release
induced by ATP alone. One study using human cord blood
derived mast cells found that ATP or ADP alone did not in-
duce β-hexosaminidase release but together were a weak
stimulus for release; in addition, they both modified IgE-
dependent secretion [21]. Similar results were obtained from
HLMCs, where a potentiation of IgE-mediated secretion by
ATP was attributed to P2Y1 and P2Y2 receptors [20]. The
potential for P2X receptors to modify other mast cell func-
tions, including the cocktail of mediators secreted under dif-
ferent stimulus conditions, warrants further investigation. In
addition to regulated exocytosis of preformed mediators, “ac-
tivated” mast cells synthesise lipid mediators, cytokines,
chemokines and growth factors which can be released inde-
pendently or in consort with preformed mediators. Calcium
plays a key role in regulating the synthesis of most of these
mediators; it is possible and probable that calcium signals
generated by the P2X receptor subtypes identified in human
mast cells can also influence eicosanoid and cytokine/
chemokine synthesis and thereby influence mast cell functions
in health and disease.
The release of pro-inflammatory mediators is a key part of
the development of the symptoms of allergic disease [40], and
identifying any receptors or ion channels contributing to this
could lead to novel therapeutic targets. Through their partici-
pation in type 1 hypersensitivity reactions, mast cells are in-
volved in a range of allergic disorders including atopic derma-
titis, anaphylaxis and asthma. Following an initial allergic
reaction, for example in the lung of an asthmatic, an acute
inflammatory reaction occurs in the surrounding tissues [41].
As this response takes effect, ATP levels would be expected to
rise in the extracellular environment, possibly contributed to
by release from mast cells themselves [42]. In support of this,
elevated levels of ATP and its breakdown product adenosine
have been found in BAL fluid of asthmatics [43, 44]. This
provides a pathway for the activation of P2Y, P2X and aden-
osine receptors on multiple cell types within the lung, includ-
ing mast cells, and the importance of ATP and adenosine in
Fig. 8 β-Hexosaminidase release in response to BzATP in LAD 2 cells.
a Dose-dependent release of β-hexosaminidase from LAD 2 cells in
response to BzATP which can be inhibited by AZ 11645373 (one-way
ANOVA, post hoc Tukey test, p < 0.05,N = 4). b Lack of BzATP induced
cytotoxicity in LAD 2 cells as measured by LDH release
244 Purinergic Signalling (2016) 12:235–246
asthma has been demonstrated by the finding that they can
both induce bronchoconstriction in asthmatic patients [45,
46]. Recent reports on the lower asthma rates in children with
attenuated P2X7 function further support a role for P2X7 re-
ceptors in the process and their importance as a therapeutic
target [22].
We have previously demonstrated the presence of function-
al P2X7 receptors in human lung mast cells [25]; given the
recent corroborating evidence for the involvement of P2X7
receptors in asthma risk and severity in children, and in anoth-
er chronic inflammatory condition involvingmast cells, name-
ly Crohn’s disease, the results of our study strongly support
the potential repositioning of P2X7 selective antagonists for
the treatment of chronic inflammatory conditions in which
mast cells play a significant role.
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